Squarepoint Ops LLC Invests $58,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Squarepoint Ops LLC bought a new position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 14,059 shares of the company’s stock, valued at approximately $58,000.

Several other institutional investors also recently modified their holdings of TRVI. Summit Investment Advisors Inc. grew its position in shares of Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after buying an additional 2,894 shares during the period. Raymond James Financial Inc. bought a new position in shares of Trevi Therapeutics during the 4th quarter valued at about $49,000. Two Sigma Advisers LP bought a new position in shares of Trevi Therapeutics during the 4th quarter valued at about $66,000. Cantor Fitzgerald L. P. bought a new position in shares of Trevi Therapeutics during the 4th quarter valued at about $82,000. Finally, ProShare Advisors LLC lifted its holdings in shares of Trevi Therapeutics by 86.4% during the 4th quarter. ProShare Advisors LLC now owns 20,685 shares of the company’s stock valued at $85,000 after purchasing an additional 9,589 shares in the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Oppenheimer reiterated an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, June 2nd. D. Boral Capital reiterated a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a report on Monday, June 2nd. Wall Street Zen cut Trevi Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, June 6th. B. Riley reiterated a “buy” rating and set a $20.00 price objective (up previously from $11.00) on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Finally, HC Wainwright assumed coverage on Trevi Therapeutics in a report on Wednesday, May 28th. They set a “buy” rating and a $21.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $18.63.

Insider Buying and Selling at Trevi Therapeutics

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 5,263 shares of the business’s stock in a transaction that occurred on Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the sale, the chief executive officer now owns 213,313 shares in the company, valued at approximately $1,403,599.54. The trade was a 2.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 18.30% of the company’s stock.

Trevi Therapeutics Stock Performance

NASDAQ TRVI opened at $6.51 on Wednesday. The stock has a market capitalization of $650.30 million, a price-to-earnings ratio of -14.80 and a beta of 0.59. The stock’s 50 day moving average price is $6.27 and its two-hundred day moving average price is $5.05. Trevi Therapeutics, Inc. has a 52 week low of $2.36 and a 52 week high of $7.48.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.04. On average, equities research analysts forecast that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.